Astellas Pharma US | Changing Tomorrow

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy

Astellas Announces Key Leadership Appointments within Oncology and Patient Centricity Organizations Read More

Astellas Celebrates Decade of Service by Volunteering 80,000 Hours to Help Local Communities Read More

Astellas Ranks in Top 10 of Working Mother Best Companies list Read More

News

Latest

News / Media

Sep 02, 2019

RIKEN and Astellas Enter into Worldwide Exclusive Licensing Agreement for Artificial Adjuvant Vector Cell Technology in Oncology

News / Media

Aug 09, 2019

Yokohama City University, Tokyo University of the Arts and Astellas Launched Health Mock Lab. to Create New Digital Healthcare Solutions Using Gamification

News / Media

Aug 06, 2019

Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

News / Corporate Awards

Oct 10, 2019

Astellas earns spot on Working Mother's Best Companies for Dads List

News / Corporate

Oct 01, 2019

Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy

News / Corporate

Sep 30, 2019

Astellas Oncology Announces 2019 C3 Prize® Finalists

View All >>